Evaluation of the Clinical and Laboratory Standards Institute phenotypic confirmatory test to detect the presence of extended-spectrum β-lactamases from 4005 Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae and Proteus mirabilis isolates

References

1. CLSI 2010; Performance Standards for Antimicrobial Susceptibility Testing; 20th Informational Supplement M100-S20. Wayne, PA: Clinical and Laboratory Standards Institute;
   [Google Scholar]
2. CLSI 2012a; Performance Standards for Antimicrobial Susceptibility Testing; 22nd Informational Supplement M100-S22. Wayne, PA: Clinical and Laboratory Standards Institute;
   [Google Scholar]
3. CLSI 2012b; Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard, 9th edn, M7-A9. Wayne, PA: Clinical and Laboratory Standards Institute;
   [Google Scholar]
4. Ellington M. J., Kistler J., Livermore D. M., Woodford N. 2007; Multiplex PCR for rapid detection of genes encoding acquired metallo-β-lactamases. J Antimicrob Chemother 59:321–322 [View Article][PubMed]
   [Google Scholar]
5. EUCAST 2013; EUCAST Clinical Breakpoints v.3. European Committee on Antimicrobial Susceptibility Testing. http://www.eucast.org/clinical_breakpoints/
6. Leclercq R., Cantón R., Brown D. F., Giske C. G., Heisig P., MacGowan A. P., Mouton J. W., Nordmann P., Rodloff A. C.& other authors ( 2011; EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect 19:141–160 [View Article][PubMed]
   [Google Scholar]
7. Livermore D. M., Canton R., Gniadkowski M., Nordmann P., Rossolini G. M., Arlet G., Ayala J., Coque T. M., Kern-Zdanowicz I.& other authors ( 2007; CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother 59:165–174 [View Article][PubMed]
   [Google Scholar]
8. Livermore D. M., Andrews J. M., Hawkey P. M., Ho P. L., Keness Y., Doi Y., Paterson D., Woodford N. 2012; Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly?. J Antimicrob Chemother 67:1569–1577 [View Article][PubMed]
   [Google Scholar]
9. Munier G. K., Johnson C. L., Snyder J. W., Moland E. S., Hanson N. D., Thomson K. S. 2010; Positive extended-spectrum-β-lactamase (ESBL) screening results may be due to AmpC β-lactamases more often than to ESBLs. J Clin Microbiol 48:673–674 [View Article][PubMed]
   [Google Scholar]
10. Nordmann P., Cuzon G., Naas T. 2009; The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 9:228–236 [View Article][PubMed]
    [Google Scholar]
11. Pérez-Pérez F. J., Hanson N. D. 2002; Detection of plasmid-mediated AmpC β-lactamase genes in clinical isolates by using multiplex PCR. J Clin Microbiol 40:2153–2162 [View Article][PubMed]
    [Google Scholar]
12. Polsfuss S., Bloemberg G. V., Giger J., Meyer V., Hombach M. 2012; Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and CLSI screening parameters for the detection of extended-spectrum β-lactamase production in clinical Enterobacteriaceae isolates. J Antimicrob Chemother 67:159–166 [View Article][PubMed]
    [Google Scholar]
13. Solomkin J. S., Dellinger E. P., Christou N. V., Busuttil R. W. 1990; Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intra-abdominal infections. Ann Surg 212:581–591 [View Article][PubMed]
    [Google Scholar]
14. Walsh T. R., Toleman M. A., Poirel L., Nordmann P. 2005; Metallo-β-lactamases: the quiet before the storm?. Clin Microbiol Rev 18:306–325 [View Article][PubMed]
    [Google Scholar]
15. Woodford N., Zhang J., Warner M., Kaufmann M. E., Matos J., Macdonald A., Brudney D., Sompolinsky D., Navon-Venezia S., Livermore D. M. 2008; Arrival of Klebsiella pneumoniae producing KPC carbapenemase in the United Kingdom. J Antimicrob Chemother 62:1261–1264 [View Article][PubMed]
    [Google Scholar]